Physician profile
Daniel E Zelac
NPI 1891709903
$43,312.28
in general payments reported to CMS, 2019-2025
35 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what 87% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $1,226 · 2021: $5,461 · 2022: $18K · 2023: $14K · 2024: $2,000 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $4,095 · Travel and Lodging: $2,363 · Long Term Medical Supply Or Device Loan: $567 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,494.00 |
| Food and Beverage | $4,095.25 |
| Travel and Lodging | $2,362.94 |
| Long Term Medical Supply Or Device Loan | $567.00 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20,886.88 | 2019-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $17,339.65 | 2019-2025 | |
| Integra Lifesciences Corporation | $686.42 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Janssen Biotech, INC. | $565.42 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $494.48 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $478.62 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Abbvie INC. | $413.78 | 2019-2025 | Rinvoq |
| Arcutis Biotherapeutics, INC. | $360.20 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $260.05 | 2020-2025 | Winlevi, Absorica Ld |
| Ucb, INC. | $256.74 | 2022-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $235.71 | 2024-2025 | Nemluvio, Aklief |
| Acera Surgical, INC. | $190.36 | 2024-2025 | Restrata Wound Matrix |
| Incyte Corporation | $188.05 | 2022-2025 | Opzelura |
| Pfizer INC. | $174.10 | 2019-2025 | |
| Organon LLC | $150.00 | 2025 | Vtama |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $88.85 | 2023-2025 | Anzupgo, Adbry |
| Amgen INC. | $66.90 | 2021-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $63.63 | 2025 | |
| Smith+Nephew, INC. | $63.09 | 2024 | Stravix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.87 | 2019-2020 | |
| Dermavant Sciences, INC. | $34.96 | 2024 | Vtama |
| Biofrontera INC. | $28.51 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Merck Sharp & Dohme LLC | $25.46 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.97 | 2020 | |
| Verrica Pharmaceuticals INC. | $23.56 | 2024 | Ycanth |
| Almirall LLC | $21.79 | 2025 | Klisyri |
| Kerecis Limited | $20.98 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sanofi-Aventis U.S. LLC | $20.19 | 2021 | |
| Seagen INC. | $17.97 | 2019 | |
| Convatec INC. | $17.64 | 2025 | |
| Genentech USA, INC. | $17.48 | 2020 | |
| Organogenesis INC. | $16.55 | 2024 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Bioventus LLC | $14.10 | 2022 | |
| Dermira, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Zelac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.